Immune response to faecal supernatant of anti-TNF treated IBD patients
Research type
Research Study
Full title
Study of monocyte/macrophage responses to faecal supernatants of anti-TNF responsive and non-responsive IBD patients.
IRAS ID
264405
Contact name
Jonathan Landy
Contact email
Sponsor organisation
West Hertfordshire Hospitals NHS Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Anti-TNF therapies remain the mainstay biologic for inflammatory bowel disease (IBD) patients. These are hugely costly and the efficacy of any one of these agents are still limited with side-effects that can be potentially severe and life-threatening. Between 20–40% of patients do not respond to anti-TNF therapies and a further 25% of patients lose response over the first year of treatment. Predictors of efficacy for anti-TNF treatment would be extremely useful in clinical practice in order to optimise treatments and to minimise side-effects and costs. There is an urgent need to personalise therapeutic choices to avoid unnecessary delays in treatment benefit, avoidance of adverse effects and to reduce costs.
Recent data suggest that the microbiota may offer a non-invasive predictive tool to predict response to anti-TNF therapy as well as response to other biologic therapies. Macrophage (immune cell) expression of inflammatory regulators that respond to microbial signalling were also recently identified as potential predictors of anti-TNF therapy response and that an altered microbiome composition may influence expression of macrophage inflammatory regulator expression and subsequently anti-TNF responsiveness.
We aim to conduct this pilot study to assess differences of macrophage characteristics when co-cultured with faecal supernatants from anti-TNF responders and non-responders.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
22/EE/0048
Date of REC Opinion
4 Apr 2022
REC opinion
Further Information Favourable Opinion